---
title: "EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294368697.md"
description: "Imunon Inc. (NASDAQ:IMNN) announced accelerated enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029. Enrollment rates exceed industry benchmarks, with strong safety data showing no serious adverse events. The company aims for potential early regulatory approval via interim analyses. Shares rose 1.95% to $1.57 in premarket trading."
datetime: "2026-07-30T12:30:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294368697.md)
  - [en](https://longbridge.com/en/news/294368697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294368697.md)
---

# EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

Clinical-stage biotechnology firm **Imunon Inc.** (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients.

The company reported site activation and patient enrollment speeds that significantly outpace original forecasts and standard industry benchmarks.

## Enrollment Rates Exceed Industry Benchmarks

The trial progressed from protocol submission to site activation in roughly six months. It reached its first randomized patient within two months of approval—one-third of the standard industry benchmark.

Current study-level enrollment stands at approximately 0.5 patients per site each month, beating the company’s initial target of 0.3 and historical industry averages of roughly 0.2. Over 70% of active sites are currently matching or surpassing the projected monthly targets.

## Clinical Timeline And Interim Regulatory Goals

Imunon now projects full enrollment completion by the second quarter of 2029.

High conversion rates from pre-screening to randomization, backed by promising overall survival data from the Phase 2 OVATION 2 study, have fueled participant interest.

Furthermore, two pre-planned interim analyses are scheduled to potentially enable an early Biologics License Application submission for full regulatory approval if specific targets are reached.

## Strong Safety Profile Confirmed

IMNN-001 has maintained a favorable safety and tolerability profile throughout the trial.

Researchers observed no instances of cytokine release syndrome, systemic toxicities, or serious immune-related adverse events. Safety outcomes remain comparable between the treatment arm (IMNN-001 with neoadjuvant and adjuvant chemotherapy) and the control arm, consistent with findings from an ongoing Phase 2 Minimal Residual Disease study.

Recent Independent Data Monitoring Committee reviews noted no safety concerns across ongoing studies.

**IMNN Stock Price Activity**: Imunon shares were up 1.95% at $1.57 during premarket trading Thursday, according to Benzinga Pro data.

**Read Also: Diners Return To Chipotle, Giving Earnings And Stock A Lift**

_Photo by Aunt Spray via Shutterstock_

### Related Stocks

- [IMNN.US](https://longbridge.com/en/quote/IMNN.US.md)
- [CMG.US](https://longbridge.com/en/quote/CMG.US.md)

## Related News & Research

- [Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan](https://longbridge.com/en/news/294371031.md)
- [Imunon announces press release available](https://longbridge.com/en/news/293625903.md)
- [Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients](https://longbridge.com/en/news/293343936.md)
- [IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development | IMNN Stock News](https://longbridge.com/en/news/293627757.md)
- [Imunon General Counsel Susan Eylward disposes of 2,150 common shares worth $3,830.44](https://longbridge.com/en/news/293382036.md)